Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Alings

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
European Heart Journal|September 11, 2019
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trialTamar I de Vries, John W Eikelboom, Jackie Bosch, et al.
Thrombosis Research|May 14, 2026
Sex differences in gastrointestinal bleeding among patients with cardiovascular diseases: A secondary analysis of the INTERBLEED studyYaoyao Cai, Jacqueline Bosch, Jun Zhu, et al.
European Heart Journal|May 10, 2026
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trialPeter van der Meer, Dirk J van Veldhuisen, Geert H D Voordes, et al.
European Journal of Heart Failure|June 14, 2013
Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II studyBart A Mulder, Dirk J Van Veldhuisen, Harry J G M Crijns, et al.
The Lancet. Neurology|May 11, 2012
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialJ Donald Easton, Renato D Lopes, M Cecilia Bahit, et al.
Journal of the American College of Cardiology|August 20, 2011
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) studyMarcelle D Smit, Harry J G M Crijns, Jan G P Tijssen, et al.
Heart (British Cardiac Society)|September 14, 2018
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillationChristina Christersson, Lars Wallentin, Ulrika Andersson, et al.
Diabetes, Obesity & Metabolism|September 2, 2025
Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trialAlina N Saidi, Laura A M Konings, Carmen A W Dietvorst, et al.
American Heart Journal|June 20, 2017
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trialRenato D Lopes, Marco Alings, Stuart J Connolly, et al.
Circulation|May 18, 2011
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialJohn W Eikelboom, Lars Wallentin, Stuart J Connolly, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
European Heart Journal|September 11, 2019
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trialTamar I de Vries, John W Eikelboom, Jackie Bosch, et al.
Thrombosis Research|May 14, 2026
Sex differences in gastrointestinal bleeding among patients with cardiovascular diseases: A secondary analysis of the INTERBLEED studyYaoyao Cai, Jacqueline Bosch, Jun Zhu, et al.
European Heart Journal|May 10, 2026
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trialPeter van der Meer, Dirk J van Veldhuisen, Geert H D Voordes, et al.
European Journal of Heart Failure|June 14, 2013
Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II studyBart A Mulder, Dirk J Van Veldhuisen, Harry J G M Crijns, et al.
The Lancet. Neurology|May 11, 2012
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialJ Donald Easton, Renato D Lopes, M Cecilia Bahit, et al.
Journal of the American College of Cardiology|August 20, 2011
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) studyMarcelle D Smit, Harry J G M Crijns, Jan G P Tijssen, et al.
Heart (British Cardiac Society)|September 14, 2018
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillationChristina Christersson, Lars Wallentin, Ulrika Andersson, et al.
Diabetes, Obesity & Metabolism|September 2, 2025
Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trialAlina N Saidi, Laura A M Konings, Carmen A W Dietvorst, et al.
American Heart Journal|June 20, 2017
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trialRenato D Lopes, Marco Alings, Stuart J Connolly, et al.
Circulation|May 18, 2011
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialJohn W Eikelboom, Lars Wallentin, Stuart J Connolly, et al.
Pageof 13